At the American Society of Hematology (ASH) meeting in Orlando, CLL expert Dr. Jan Burger discussed the result from the RESONATE-2 trial, which studied the use of ibrutinib (Imbruvica) vs. chlorambucil in the frontline setting in patients over 65. Dr. Burger reviews the medications benefits in overall survival, progression free survival, and in response rates. Learn why Dr. Burger feels it is compelling to use ibrutinib more in the frontline setting for elderly patients.
Get email alerts | http://www.patientpower.info/alerts
Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo